B
Brandy M. Heckman-Stoddard
Researcher at National Institutes of Health
Publications - 49
Citations - 1188
Brandy M. Heckman-Stoddard is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 12, co-authored 33 publications receiving 846 citations.
Papers
More filters
Journal ArticleDOI
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis taking into account Biases and Confounders
Sara Gandini,Matteo Puntoni,Brandy M. Heckman-Stoddard,Barbara K. Dunn,Leslie G. Ford,Andrea Decensi,Eva Szabo +6 more
TL;DR: The results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally.
Journal ArticleDOI
Repurposing metformin for the prevention of cancer and cancer recurrence
TL;DR: Examination of metformin’s chemopreventive potential is examined by outlining relevant mechanisms of action, the most recent epidemiologic evidence, and recently completed and ongoing clinical trials.
Journal ArticleDOI
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Vanita R. Aroda,Vanita R. Aroda,Vanita R. Aroda,William C. Knowler,Jill P. Crandall,Leigh Perreault,Sharon L. Edelstein,Susan Jeffries,Mark E. Molitch,Xavier Pi-Sunyer,Christine Darwin,Brandy M. Heckman-Stoddard,Marinella Temprosa,Steven E. Kahn,David M. Nathan +14 more
TL;DR: Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin’s potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer.
Journal ArticleDOI
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug
Matteo Lazzeroni,Davide Serrano,Barbara K. Dunn,Brandy M. Heckman-Stoddard,Oukseub Lee,Seema A. Khan,Andrea Decensi +6 more
TL;DR: Findings suggest possible beneficial clinical preventive effects by low-dose tamoxifen regimens and they are supported by observational studies.
Journal ArticleDOI
A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones
H-H. Sherry Chow,Linda L. Garland,Brandy M. Heckman-Stoddard,Chiu Hsieh Hsu,Valerie D. Butler,Catherine A. Cordova,Wade M. Chew,Terri L. Cornelison +7 more
TL;DR: It is concluded that among overweight and obese postmenopausal women, daily 1 gm dose of resveratrol has favorable effects on estrogen metabolism and SHBG.